| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,380 | 1,685 | 06.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BACTIGUARD Aktie jetzt für 0€ handeln | |||||
| Do | Bactiguard Holding AB: Bactiguard Holding AB's year-end report 2025 | 75 | GlobeNewswire (Europe) | A year of strategic execution concluded with a strong Q4
Fourth quarter 2025 (October - December)
Total revenue amounted to SEK 65.6 (68.3) million, a decrease of SEK 2.7 million corresponding to... ► Artikel lesen | |
| 29.01. | BACTIGUARD HOLDING AB: Invitation to presentation of Bactiguard's year-end report for 2025 | 1 | Cision News | ||
| 19.12.25 | Bactiguard Holding AB: Bactiguard announces updated trauma license agreement with Zimmer Biomet | 222 | GlobeNewswire (Europe) | Bactiguard continues the collaboration with Zimmer Biomet in an updated agreement, giving Zimmer Biomet non-exclusive rights to continue to commercialize the ZNN Bactiguard coated trauma nail system... ► Artikel lesen | |
| 07.11.25 | BACTIGUARD HOLDING AB: Nomination Committee appointed for Bactiguard Holding AB's Annual General Meeting 2026 | 1 | Cision News | ||
| 23.10.25 | Bactiguard Holding AB: Bactiguard Holding AB's interim report third quarter 2025 | 191 | GlobeNewswire (Europe) | Continued profitability and clinical evidence supporting future growth
Third quarter 2025 (July - September)
Total revenue amounted to SEK 48.4 (73.9) million, a decrease of SEK 25.5 million corresponding... ► Artikel lesen | |
| 16.10.25 | BACTIGUARD HOLDING AB: Invitation to presentation of Bactiguard's interim report for the third quarter 2025 | 3 | Cision News | ||
| 29.09.25 | BACTIGUARD HOLDING AB: Independent studies expand clinical evidence on Bactiguard's technology in orthopedics | 1 | Cision News | ||
| 15.07.25 | Bactiguard Holding AB: Bactiguard Holding AB's interim report second quarter 2025 | 274 | GlobeNewswire (Europe) | Positive EBITDA momentum carried forward in Q2
Second quarter 2025 (April - June)
Total revenue amounted to SEK 52.1 (60.9) million, a decrease of SEK 8.8 million corresponding to 14.4%.
Net sales... ► Artikel lesen | |
| 15.05.25 | Bactiguard Holding AB: Bulletin from Bactiguard Holding AB's (publ) Annual General Meeting | 284 | GlobeNewswire (Europe) | At Bactiguard Holding AB's (publ) Annual General Meeting (AGM) on 15 May 2025, the following resolutions were made:
The AGM adopted the income statements and balance sheets for 2024 and decided that... ► Artikel lesen | |
| 24.04.25 | Bactiguard Holding AB: Bactiguard Holding AB's interim report first quarter 2025 | 224 | GlobeNewswire (Europe) | Continued profitability and revenue growth for Bactiguard
First quarter 2025 (January - March)
Total revenue amounted to SEK 62.7 (58.8) million, an increase of SEK 3.9 million corresponding to 6.7%.
Net... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 4,240 | -0,05 % | Teladoc Health, Inc.: Teladoc Health to Announce Fourth Quarter 2025 Financial Results | ||
| ROKU | 73,07 | +0,63 % | This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday | ||
| SERNOVA BIOTHERAPEUTICS | 0,086 | -7,53 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 63,80 | -1,24 % | ROUNDUP: Boston Scientific Guides Q1, FY26 In Line With Estimates | WASHINGTON (dpa-AFX) - While reporting financial results for the fourth quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) initiated its adjusted earnings and sales... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB AG: Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort | EQS-News: SYNLAB
/ Schlagwort(e): Strategische Unternehmensentscheidung
Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort
23.10.2025... ► Artikel lesen | |
| PAUL HARTMANN | 222,00 | -0,89 % | Vorläufiges Jahresergebnis 2025: PAUL HARTMANN steigert erneut Umsatz und Ergebnis | Heidenheim (ots) - Die HARTMANN GRUPPE hat im Geschäftsjahr 2025 ein vorläufiges organisches Umsatzwachstum von 2,2 % erzielt.Das vorläufige bereinigte EBITDA liegt mit 277 Mio. EUR um rund 15 Mio.... ► Artikel lesen | |
| SYSMEX | 8,150 | 0,00 % | Fujirebio und Sysmex beginnen Vertriebskooperation für Demenz-Tests | Fujirebio Holdings, Inc. (Zentrale: Minato-ku, Tokio; President CEO: Goki Ishikawa; "Fujirebio"), eine konsolidierte Tochtergesellschaft der H.U. Group Holdings, Inc. (Zentrale: Minato-ku, Tokio;... ► Artikel lesen | |
| ADDLIFE | 14,370 | -0,83 % | AddLife AB: Year-end report January 1 - December 31, 2025 | Continued positive margin development, strong profit and cash flow"The EBITA margin continues to develop positively and profits are growing. The strong cash flow means that our ambition to reduce the... ► Artikel lesen | |
| EMBECTA | 9,150 | -0,54 % | Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results | PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical... ► Artikel lesen | |
| COVETRUS | - | - | Mars Petcare, epiq Animal Health enter distribution agreement: Previously only available through Covetrus, Greenies will ... | ||
| ENOVIS | 19,000 | -0,52 % | Enovis Corporation: Enovis Appoints Oliver Engert as Chief Administrative Officer | Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers mit einem Kursziel von 60 Euro auf "Buy" belassen. Der Aktienkurs der Münchner spiegle die mittelfristigen... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | DAX-Check LIVE: Fresenius Medical Care, Nordex, Puma, Sartorius Vz., Schaeffler, Siltronic im Fokus | Ein kurzzeitiger Ausverkauf bei Gold und Silber hat den DAX zum Wochenstart zunächst belastet. Die Unsicherheit beruhigte sich jedoch im Tagesverlauf, auch unterstützt durch eine Erholung an den US-Märkten.... ► Artikel lesen | |
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |